

GLOBAL LIFE SCIENCES FUND - CLASS A SGD ACC HEDGED

Fund facts at 31 December 2019 Date of issue: 14 January 2020

Structure

Irish Investment Company

Fund launch date

31 March 2000

Share class launch date

11 March 2019

Base currency

USD

Fund size (USD)

2.59bn

Benchmark

MSCI World Health Care

Minimum investment (SGD)

2,500

NAV (SGD)

11.31

Maximum initial charge

5.00%

Annual management charge (AMC)

1.50% pa

Total expense ratio (TER)

2.42%

Codes

ISIN: IE00BJT1NW94

Sedol: BJT1NW9

Valor: 46796359

WKN: A2PFGT

Fund aim

This global health care fund seeks consistent returns by investing in companies addressing unmet medical needs or making the health care system more efficient. We balance the portfolio across pharmaceuticals, biotechnology and services/devices sub-sectors in an effort to achieve similar or lower volatility relative to our peers.

Key points

- Global approach to companies that are meeting unmet medical needs and providing efficient and cost-effective healthcare solutions.
- Differentiated fundamental research: We seek to understand the science and the business.
- Disciplined valuation analysis and diversification across industries, geographies and market capitalisation.

Additional information

The MSCI World Healthcare index is a reference benchmark for performance reporting only. Information relating to other currencies and fee structure can be found in the fund prospectus. Refer to Annual Report and Accounts for more information on fees and expenses, AMC included.

Fund managers

Andy Acker, CFA

Top 10 holdings	(%)	Industry breakdown	(%)
Merck & Co Inc	4.4	Pharmaceuticals	35.8
Novartis AG (ADR)	4.2	Biotechnology	27.3
Abbott Laboratories	3.2	Health Care Equipment	15.6
UnitedHealth Group Inc	3.2	Managed Health Care	8.8
AstraZeneca PLC	3.0	Life Sciences Tools & Services	4.8
Bristol-Myers Squibb Co	3.0	Health Care Supplies	4.0
Thermo Fisher Scientific Inc	2.9	Health Care Facilities	1.2
Humana Inc	2.5	Health Care Services	0.9
Anthem Inc	2.5	Health Care Technology	0.7
Takeda Pharmaceutical Co Ltd	2.4		
Total number of positions	98		

Performance

No share class performance is shown because the share class is less than one year old.

Market capitalisation

	(%)
Over \$100B	36.2
\$50B to \$100B	15.2
\$10B to \$50B	15.3
\$5B to \$10B	11.9
\$1B to \$5B	13.5
\$500M to \$1B	2.2
\$250M to \$500M	0.1
\$100M to \$250M	0.1
N/A	4.8

GLOBAL LIFE SCIENCES FUND - CLASS A SGD ACC HEDGED

(continued)

What are the risks specific to this fund?

- This fund is designed to be used only as one component of several in a diversified investment portfolio. Investors should consider carefully the proportion of their portfolio invested into this fund.
- Shares can lose value rapidly, and typically involve higher risks than bonds or money market instruments. The value of your investment may fall as a result.
- Shares of small and mid-size companies can be more volatile than shares of larger companies, and at times it may be difficult to value or to sell shares at desired times and prices, increasing the risk of losses.
- If a Fund has a high exposure to a particular country or geographical region it carries a higher level of risk than a Fund which is more broadly diversified.
- The Fund is focused towards particular industries or investment themes and may be heavily impacted by factors such as changes in government regulation, increased price competition, technological advancements and other adverse events.
- The Fund may use derivatives with the aim of reducing risk or managing the portfolio more efficiently. However this introduces other risks, in particular, that a derivative counterparty may not meet its contractual obligations.
- If the Fund holds assets in currencies other than the base currency of the Fund or you invest in a share class of a different currency to the Fund (unless 'hedged'), the value of your investment may be impacted by changes in exchange rates.

General risks

- Past performance is not a guide to future performance.
- The value of an investment and income can fall as well as rise and you may not get back the amount originally invested.
- Tax assumptions and reliefs depend upon an investor's particular circumstances and may be subject to change.

For further information please visit our website at www.janushenderson.com/sg

GLOBAL LIFE SCIENCES FUND - CLASS A SGD ACC HEDGED

(continued)

Janus Henderson
INVESTORS

Important information

For hedged share classes the appropriate index is the hedged version of the mandated benchmark. Only share class returns are displayed as we do not currently subscribe to this index. Source: Janus Henderson Investors unless stated otherwise. This document has been prepared by Janus Henderson Investors (Singapore) Limited, the Singapore Representative of the Fund. The Fund is distributed by authorised distributors. The prospectus and Product Highlights Sheet ("PHS") of the Fund are available and may be obtained from the Singapore Representative's office and the authorized distributors' offices. Investors should read the prospectus and PHS before deciding whether to invest in the shares of the Fund. The Fund may employ investment techniques and instruments for investment purposes, such as trading in futures, options and swaps and other financial derivative instruments. Issued in Singapore by Janus Henderson Investors (Singapore) Limited, licensed and regulated by the Monetary Authority of Singapore, Company Registration No. 199700782N. Janus Henderson Capital Funds Plc is a UCITS established under Irish law, with segregated liability between funds. Janus Capital International Limited acts as the investment adviser to JHCF. Janus Capital Management LLC ("Janus") acts as sub-investment adviser of the Fund to Janus Capital International Limited. This is neither an offer nor solicitation to purchase Shares of the Fund. Investors are warned that they should only make their investments based on the most recent offering documents which contains information about fees, expenses and risks, which is available from all distributors and paying agents, and which should be read carefully. An investment in the Fund may not be suitable for all investors and is not available to all investors in all jurisdictions. In particular, it is not available to US persons. The rate of return may vary and the principal value of an investment will fluctuate due to market and foreign exchange movements. Shares, if redeemed, may be worth more or less than their original cost. In preparing this document, Janus Henderson Investors has reasonable belief to rely upon the accuracy and completeness of information available from public sources. Unless otherwise stated, the source of information is from Janus Henderson Investors. It is the intermediary's responsibility to determine the extent it may pass on this document or the information contained in it to any third party under relevant law, and to comply with all such law. Janus Henderson Investors is not responsible for any unlawful distribution of this document to any third parties. Investments are not deposits or other obligations of, guaranteed or insured by Janus Capital International Limited or any distributor or any of their affiliates, or by any local governmental or insurance agency. Dividend amount or dividend rate is not guaranteed. Positive dividend does not mean positive return. Bond credit quality ratings provided by Barclays and reflect the middle rating received from Moody's, Standard & Poor's and Fitch, where all three agencies have provided a rating. If only two agencies rate a security, the lowest rating is used. If only one agency rates a security, that rating is used. Ratings are measured on a scale that ranges from Aaa (highest) to D (lowest). Portfolio holdings are subject to change without notice. ©2019 Morningstar. All Rights Reserved. CFA® and Chartered Financial Analyst® are trademarks owned by CFA Institute. © 2019, Janus Henderson Group plc. Janus Henderson is a trademark of Janus Henderson Group plc or one of its subsidiary entities. The Fund may at its discretion (i) pay dividends out of the capital of the Fund, and (ii) pay dividends out of gross income while charging all or part of the fees and expenses to the capital of the Fund, resulting in an increase in distributable income available for the payment of dividends by the Fund and therefore, the Fund may effectively pay dividends out of capital. This may result in an immediate reduction of the Fund's net asset value per share, and it amounts to a return or withdrawal of part of an investor's original investment or from any capital gains attributable to that original investment. Past distributions are not necessarily indicative of future trends, which may be lower. The distribution frequency and details can be obtained at the website www.janushenderson.com/sg. Janus Henderson Investors (Singapore) Limited. Address: 138 Market Street, #34-03/04, CapitaGreen, Singapore 048946 Website: www.janushenderson.com/sg Company Registration No. 199700782N. **This advertisement has not been reviewed by the Monetary Authority of Singapore.**